Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product: Sprycel
Active Ingredient: Dasatinib 20mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Bristol-Myers Squibb (NZ) Company
Manufacturer: Bristol-Myers Squibb Company, Mt Vernon, Indiana, United States of America
Note: This consent is valid for two years from the date of publication of this notice.
Product: Sprycel
Active Ingredient: Dasatinib 50mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Bristol-Myers Squibb (NZ) Company
Manufacturer: Bristol-Myers Squibb Company, Mt Vernon, Indiana, United States of America
Note: This consent is valid for two years from the date of publication of this notice.
Product: Sprycel
Active Ingredient: Dasatinib 70mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Bristol-Myers Squibb (NZ) Company
Manufacturer: Bristol-Myers Squibb Company, Mt Vernon, Indiana, United States of America
Note: This consent is valid for two years from the date of publication of this notice.
Dated this 9th day of March 2007.
DON MATHESON, Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).